ITCI Intra-Cellular Therapies Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 06 April 2020 ALEXANDRIA REAL ESTATE EQUITIES, INC. (FormDEF 14A)

2. 02 April 2020 Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults

   NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

3. 02 March 2020 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

   NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

4. 24 February 2020 Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast

   NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS)

5. 21 February 2020 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

6. 20 February 2020 Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry

   NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

7. 18 February 2020 Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference

   NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

8. 07 January 2020 Intra-Cellular Therapies Prices Public Offering of Common Stock

   NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000

9. 06 January 2020 Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

   NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its

10. 02 January 2020 Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

11. 23 December 2019 FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

    NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

12. 12 December 2019 Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in

13. 04 December 2019 Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

14. 30 September 2019 Intra-Cellular Therapies to Present at the 2019 Cantor Global Healthcare Conference

    NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today

15. 25 September 2019 Intra-Cellular Therapies Announces Progression to Higher Dose Cohort in ITI-214 Translational Medicine Study in Patients with Heart Failure

    Data indicate ITI-214 at a dose of 30 mg is well tolerated with a favorable safety profile Study ‘104 now proceeding to a third cohort at a dose of 90 mg NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular

16. 10 September 2019 Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting Company has completed submission of non-clinical information previously agreed with FDA  NEW YORK, Sept. 10, 2019 (GLOBE